Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
Saved in:
| Title: | Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. |
|---|---|
| Authors: | Aquilanti E; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Kageler L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Watson J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Baird DM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Jones RE; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Hodges M; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Szegletes ZM; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Doench JG; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Strathdee CA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Figueroa JRMF; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Beck M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Wen PY; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Meyerson M; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Center for Cancer Genomics, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2023 Jul 06; Vol. 25 (7), pp. 1275-1285. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noad024 |
